SCHEMBL21296940

SCHEMBL21296940

COc1ccc(Cn2nnc(C(=O)O)c2Nc2ccc(OC)cc2)cc1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.54
KMT2A Q03164 3/20 0.54
ALOX15 P16050 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
AKR1C3 P42330 8/20 0.51
POLB P06746 3/20 0.48
MAPT P10636 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
HSD17B10 Q99714 3/20 0.47
HPGD P15428 1/20 0.47
ALDH1A1 P00352 2/20 0.46
CYP1A2 P05177 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ERCC5 P28715 1/20 0.45
FEN1 P39748 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
PDE8B O95263 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22815714 0.92 TP53 (0.54) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL22816473 0.90 MEN1 (0.48) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL22816737 0.90 ALOX15 (0.49) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL22816574 0.89 MEN1 (0.52) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL22816699 0.89 AKR1C3 (0.49) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL22815530 0.89 TP53 (0.52) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL21296896 0.88 MAPT (0.48) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL22815706 0.88 POLB (0.47) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL22816820 0.88 MEN1 (0.46) MEN1KMT2AALOX15L3MBTL1AKR1C3
SCHEMBL21296878 0.86 MEN1 (0.51) MEN1KMT2AALOX15L3MBTL1AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11389456-B2 Compounds and methods for treating oxalate-related diseases OXALURX, INC. (US) 2022-07-19 US disclosed
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2020-12-17 US disclosed
WO-2019165159-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. (US) 2019-08-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200390778-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, LOX MEN1 3426/4885KMT2A 3943/4885ALOX15 127/4885
US-11389456-B2 Compounds and methods for treating oxalate-related diseases XDH, PNPO, LOX MEN1 3426/4885KMT2A 3943/4885ALOX15 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.